Published in Free Radic Biol Med on May 28, 2008
Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease. Free Radic Biol Med (2010) 1.91
Energy deficit in Huntington disease: why it matters. J Clin Invest (2011) 1.51
Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl Psychiatry (2012) 1.35
Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna) (2009) 1.27
Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications. Antioxid Redox Signal (2012) 1.24
Recent advances in quantitative neuroproteomics. Methods (2013) 1.23
Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med (2010) 1.13
Multifunctional roles of enolase in Alzheimer's disease brain: beyond altered glucose metabolism. J Neurochem (2009) 1.12
Electromagnetic fields, oxidative stress, and neurodegeneration. Int J Cell Biol (2012) 1.10
Oxidative stress and neurodegenerative disorders. Int J Mol Sci (2013) 1.04
8OHdG as a marker for Huntington disease progression. Neurobiol Dis (2012) 1.00
Huntington's disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the Drosophila heart. PLoS Genet (2013) 1.00
Antioxidants in Huntington's disease. Biochim Biophys Acta (2011) 1.00
Chemical probes for analysis of carbonylated proteins: a review. J Chromatogr B Analyt Technol Biomed Life Sci (2010) 0.97
Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes. Nat Commun (2013) 0.95
A mutant light-chain ferritin that causes neurodegeneration has enhanced propensity toward oxidative damage. Free Radic Biol Med (2012) 0.94
Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis. Free Radic Biol Med (2013) 0.94
PGC-1α, mitochondrial dysfunction, and Huntington's disease. Free Radic Biol Med (2013) 0.92
Antioxidant gene therapy against neuronal cell death. Pharmacol Ther (2013) 0.92
Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases. Oxid Med Cell Longev (2014) 0.88
Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease. J Clin Invest (2011) 0.86
The choreography of neuroinflammation in Huntington's disease. Trends Immunol (2015) 0.85
Methionine oxidation of Sup35 protein induces formation of the [PSI+] prion in a yeast peroxiredoxin mutant. J Biol Chem (2011) 0.85
S-nitrosylation of dynamin-related protein 1 mediates mutant huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington's disease. Antioxid Redox Signal (2013) 0.85
Probucol increases striatal glutathione peroxidase activity and protects against 3-nitropropionic acid-induced pro-oxidative damage in rats. PLoS One (2013) 0.84
Dithiol-based compounds maintain expression of antioxidant protein peroxiredoxin 1 that counteracts toxicity of mutant huntingtin. J Biol Chem (2012) 0.80
Changes in the striatal proteome of YAC128Q mice exhibit gene-environment interactions between mutant huntingtin and manganese. J Proteome Res (2012) 0.80
Mitochondrial functional alterations in relation to pathophysiology of Huntington's disease. J Bioenerg Biomembr (2010) 0.80
The role of the cofilin-actin rod stress response in neurodegenerative diseases uncovers potential new drug targets. Bioarchitecture (2012) 0.80
Proteomic Analysis of Dynein-Interacting Proteins in Amyotrophic Lateral Sclerosis Synaptosomes Reveals Alterations in the RNA-Binding Protein Staufen1. Mol Cell Proteomics (2015) 0.80
Targeting sirtuin-1 in Huntington's disease: rationale and current status. CNS Drugs (2013) 0.79
Downregulation of genes involved in metabolism and oxidative stress in the peripheral leukocytes of Huntington's disease patients. PLoS One (2012) 0.78
Besides Huntington's disease, does brain-type creatine kinase play a role in other forms of hearing impairment resulting from a common pathological cause? Aging (Albany NY) (2011) 0.78
Protection by dietary restriction in the YAC128 mouse model of Huntington's disease: Relation to genes regulating histone acetylation and HTT. Neurobiol Dis (2015) 0.78
hMTH1 expression protects mitochondria from Huntington's disease-like impairment. Neurobiol Dis (2012) 0.78
Expanded ataxin-7 cause toxicity by inducing ROS production from NADPH oxidase complexes in a stable inducible Spinocerebellar ataxia type 7 (SCA7) model. BMC Neurosci (2012) 0.78
Abnormal degradation of the neuronal stress-protective transcription factor HSF1 in Huntington's disease. Nat Commun (2017) 0.78
Mitochondrial Dysfunction in Cancer and Neurodegenerative Diseases: Spotlight on Fatty Acid Oxidation and Lipoperoxidation Products. Antioxidants (Basel) (2016) 0.77
Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway. Dis Model Mech (2015) 0.77
Metabolism in HD: still a relevant mechanism? Mov Disord (2014) 0.77
Old Things New View: Ascorbic Acid Protects the Brain in Neurodegenerative Disorders. Int J Mol Sci (2015) 0.76
Qualitative and quantitative multiplexed proteomic analysis of complex yeast protein fractions that modulate the assembly of the yeast prion Sup35p. PLoS One (2011) 0.76
Redox Modulations, Antioxidants, and Neuropsychiatric Disorders. Oxid Med Cell Longev (2015) 0.75
Discovery of Age-Related Protein Folding Stability Differences in the Mouse Brain Proteome. J Proteome Res (2016) 0.75
Protective Effect of Antioxidants on Neuronal Dysfunction and Plasticity in Huntington's Disease. Oxid Med Cell Longev (2017) 0.75
Enhanced neuronal glucose transporter expression reveals metabolic choice in a HD Drosophila model. PLoS One (2015) 0.75
Network analysis of human post-mortem microarrays reveals novel genes, microRNAs, and mechanistic scenarios of potential importance in fighting huntington's disease. Comput Struct Biotechnol J (2016) 0.75
Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease. Hum Mol Genet (2016) 0.75
Crystallization and preliminary crystallographic analysis of mouse peroxiredoxin II with significant pseudosymmetry. Acta Crystallogr Sect F Struct Biol Cryst Commun (2010) 0.75
Protein aggregation activates erratic stress response in dietary restricted yeast cells. Sci Rep (2016) 0.75
Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington's disease. Funct Neurol (2015) 0.75
Synthetic lethal screening in the mammalian central nervous system identifies Gpx6 as a modulator of Huntington's disease. Proc Natl Acad Sci U S A (2014) 0.75
Oxidative Stress and Huntington's Disease: The Good, The Bad, and The Ugly. J Huntingtons Dis (2016) 0.75
Selective A2A receptor antagonist SCH 58261 modulates striatal oxidative stress and alleviates toxicity induced by 3-Nitropropionic acid in male Wistar rats. Metab Brain Dis (2017) 0.75
Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications. Oxid Med Cell Longev (2017) 0.75
Long non-coding antisense RNA controls Uchl1 translation through an embedded SINEB2 repeat. Nature (2012) 3.08
Grx5 is a mitochondrial glutaredoxin required for the activity of iron/sulfur enzymes. Mol Biol Cell (2002) 2.36
A DNA methylation fingerprint of 1628 human samples. Genome Res (2011) 2.16
A myriad of miRNA variants in control and Huntington's disease brain regions detected by massively parallel sequencing. Nucleic Acids Res (2010) 1.99
MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet (2011) 1.92
Redox control and oxidative stress in yeast cells. Biochim Biophys Acta (2007) 1.90
Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology (2007) 1.76
Oxidative damage to specific proteins in replicative and chronological-aged Saccharomyces cerevisiae: common targets and prevention by calorie restriction. J Biol Chem (2004) 1.62
Oxidative and endoplasmic reticulum stress interplay in sporadic amyotrophic lateral sclerosis. Brain (2007) 1.52
Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma (2005) 1.47
Dopamine induces autophagic cell death and alpha-synuclein increase in human neuroblastoma SH-SY5Y cells. J Neurosci Res (2003) 1.41
Phenotypic patterns of desminopathy associated with three novel mutations in the desmin gene. Neuromuscul Disord (2007) 1.35
Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer (2003) 1.33
Pro-NGF isolated from the human brain affected by Alzheimer's disease induces neuronal apoptosis mediated by p75NTR. Am J Pathol (2005) 1.33
Protein targets of oxidative damage in human neurodegenerative diseases with abnormal protein aggregates. Brain Pathol (2009) 1.33
Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy. Ann Neurol (2011) 1.31
Novel antioxidant role of alcohol dehydrogenase E from Escherichia coli. J Biol Chem (2003) 1.30
Early oxidative damage underlying neurodegeneration in X-adrenoleukodystrophy. Hum Mol Genet (2008) 1.27
PINK1-linked parkinsonism is associated with Lewy body pathology. Brain (2010) 1.27
Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem (2005) 1.24
Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy. Hum Mol Genet (2004) 1.23
A pathogenic mechanism in Huntington's disease involves small CAG-repeated RNAs with neurotoxic activity. PLoS Genet (2012) 1.20
Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases. Biochem J (2006) 1.18
Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med (2011) 1.16
Evidence of oxidative stress in the neocortex in incidental Lewy body disease. J Neuropathol Exp Neurol (2005) 1.15
TAR DNA-Binding protein 43 accumulation in protein aggregate myopathies. J Neuropathol Exp Neurol (2009) 1.15
MPP+ increases alpha-synuclein expression and ERK/MAP-kinase phosphorylation in human neuroblastoma SH-SY5Y cells. Brain Res (2002) 1.12
Biochemical characterization of yeast mitochondrial Grx5 monothiol glutaredoxin. J Biol Chem (2003) 1.11
Colorimetric assay for the quantitation of iron in yeast. Anal Biochem (2005) 1.09
Mitochondrial Hsp60, resistance to oxidative stress, and the labile iron pool are closely connected in Saccharomyces cerevisiae. J Biol Chem (2002) 1.08
Amyloid-targeted therapeutics in Alzheimer's disease: use of human albumin in plasma exchange as a novel approach for Abeta mobilization. Drug News Perspect (2009) 1.07
DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol (2009) 1.05
A highly expressed miR-101 isomiR is a functional silencing small RNA. BMC Genomics (2013) 1.05
Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies. BMC Genomics (2014) 1.04
Lipid alterations in lipid rafts from Alzheimer's disease human brain cortex. J Alzheimers Dis (2010) 1.04
Up-regulation of the Kv3.4 potassium channel subunit in early stages of Alzheimer's disease. J Neurochem (2004) 1.04
DnaK dependence of mutant ethanol oxidoreductases evolved for aerobic function and protective role of the chaperone against protein oxidative damage in Escherichia coli. Proc Natl Acad Sci U S A (2002) 1.02
Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: a paradigm for multifactorial neurodegenerative diseases? Biochim Biophys Acta (2012) 0.99
Structure-function analysis of yeast Grx5 monothiol glutaredoxin defines essential amino acids for the function of the protein. J Biol Chem (2002) 0.99
Clinical and myopathological evaluation of early- and late-onset subtypes of myofibrillar myopathy. Neuromuscul Disord (2011) 0.99
Reduction of oxidative cellular damage by overexpression of the thioredoxin TRX2 gene improves yield and quality of wine yeast dry active biomass. Microb Cell Fact (2010) 0.99
Molecular mechanisms of MLC1 and GLIALCAM mutations in megalencephalic leukoencephalopathy with subcortical cysts. Hum Mol Genet (2011) 0.98
Altered distribution of RhoA in Alzheimer's disease and AbetaPP overexpressing mice. J Alzheimers Dis (2010) 0.98
Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease. Neuromolecular Med (2013) 0.98
Pro-NGF from Alzheimer's disease and normal human brain displays distinctive abilities to induce processing and nuclear translocation of intracellular domain of p75NTR and apoptosis. Am J Pathol (2006) 0.97
Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid-beta and is overexpressed in dystrophic neurites in Alzheimer's brain. J Neurosci (2006) 0.96
Metabolomics of human brain aging and age-related neurodegenerative diseases. J Neuropathol Exp Neurol (2014) 0.96
Inter-laboratory assessment of PrPSc typing in creutzfeldt-jakob disease: a Western blot study within the NeuroPrion Consortium. Brain Pathol (2008) 0.95
LRRK2 and neurodegeneration. Acta Neuropathol (2009) 0.95
Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2. Mov Disord (2009) 0.95
Aquaporin expression in the cerebral cortex is increased at early stages of Alzheimer disease. Brain Res (2006) 0.95
Distinct patterns of APP processing in the CNS in autosomal-dominant and sporadic Alzheimer disease. Acta Neuropathol (2012) 0.95
Manganese is the link between frataxin and iron-sulfur deficiency in the yeast model of Friedreich ataxia. J Biol Chem (2006) 0.95
A1 adenosine receptors accumulate in neurodegenerative structures in Alzheimer disease and mediate both amyloid precursor protein processing and tau phosphorylation and translocation. Brain Pathol (2003) 0.94
Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation. Liver Transpl (2010) 0.94
Protein oxidation in Huntington disease affects energy production and vitamin B6 metabolism. Free Radic Biol Med (2010) 0.94
VDAC and ERalpha interaction in caveolae from human cortex is altered in Alzheimer's disease. Mol Cell Neurosci (2009) 0.93
Deposition of hyperphosphorylated tau in cerebellum of PS1 E280A Alzheimer's disease. Brain Pathol (2011) 0.92
Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy. Brain (2012) 0.92
Effectiveness of Ecteinascidin-743 against drug-sensitive and -resistant bone tumor cells. Clin Cancer Res (2002) 0.91
Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment. Acta Neuropathol (2010) 0.91
DNA methylation map of mouse and human brain identifies target genes in Alzheimer's disease. Brain (2013) 0.91
Complex deregulation and expression of cytokines and mediators of the immune response in Parkinson's disease brain is region dependent. Brain Pathol (2014) 0.91
Promoter hypermethylation of the phosphatase DUSP22 mediates PKA-dependent TAU phosphorylation and CREB activation in Alzheimer's disease. Hippocampus (2014) 0.91
The loss of c-Jun N-terminal protein kinase activity prevents the amyloidogenic cleavage of amyloid precursor protein and the formation of amyloid plaques in vivo. J Neurosci (2011) 0.90
Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species. J Neuropathol Exp Neurol (2015) 0.90
Transgenic mice overexpressing the full-length neurotrophin receptor TrkC exhibit increased catecholaminergic neuron density in specific brain areas and increased anxiety-like behavior and panic reaction. Neurobiol Dis (2006) 0.90
Chronological and replicative life-span extension in Saccharomyces cerevisiae by increased dosage of alcohol dehydrogenase 1. Microbiology (2007) 0.90
Oxidative damage compromises energy metabolism in the axonal degeneration mouse model of X-adrenoleukodystrophy. Antioxid Redox Signal (2011) 0.90
Glutaredoxins in fungi. Photosynth Res (2006) 0.89
Pioglitazone halts axonal degeneration in a mouse model of X-linked adrenoleukodystrophy. Brain (2013) 0.89
Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease. Parkinsonism Relat Disord (2007) 0.89
Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques. Eur J Cell Biol (2003) 0.89
Oxidative stress in desminopathies and myotilinopathies: a link between oxidative damage and abnormal protein aggregation. Brain Pathol (2007) 0.89
Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol (2003) 0.89
Neuronal death is enhanced and begins during foetal development in type I spinal muscular atrophy spinal cord. Brain (2002) 0.89
Frataxin depletion in yeast triggers up-regulation of iron transport systems before affecting iron-sulfur enzyme activities. J Biol Chem (2010) 0.89